| Name |
Description |
Page Modified |
| The Implementation of Population PK/PD in Pediatric Drug Development |
Presented at the 2003 AAPS Annual Meeting, Salt Lake City, UT |
Fri Nov 02 13:15:24 EDT 2007 |
| Pharmacokinetic/Pharmacodynamic Analysis of Data from a Phase III Trial of Linezolid IV/PO for the Treatment of Resistant Gram-Positive Bacterial Infections in Children |
Presented at the 2003 ASCPT Annual Meeting, Washington, DC |
Fri Nov 02 13:15:24 EDT 2007 |
| Development of a Novel Population Pharmacokinetic (PK)-Based Method to Describe the Time-Course of Gatifloxacin (GAT) Middle Ear Fluid (MEF) Concentrations in Children |
Presented at the the 2003 ICAAC Annual Meeting, Chicago, IL |
Mon Nov 05 11:46:39 EST 2007 |
| Population Pharmacokinetics (PK and Pharmacodynamics (PD) of Gatifloxacin (GAT) Plasma and MIddle Ear Fluid (MEF) Concentrations in Pediatric Patients with Acute Otitis Media Treatment Failures (AOM-TF) and/or Recurrent Otitis Media (ROM) |
Presented at the 2003 ICAAC Annual Meeting, Chicago, IL |
Fri Nov 02 13:15:24 EDT 2007 |
| Population Pharmacokinetics (PK) of Linezolid in Neonates and Young Infants |
Presented at the 2002 ICAAC Annual Meeting, San Diego, CA |
Fri Nov 02 13:15:24 EDT 2007 |
| Impact of Pharmacokinetic and Microbiological Variability on the Pharmacodynamics of Gatifloxacin against S. pneumoniae in Children |
Presented at the 2002 ICAAC Annual Meeting, San Diego, CA |
Fri Nov 02 13:15:24 EDT 2007 |
| A New Paradigm in Pediatric Drug Development: The Application of Cognitive Engineering |
Presented at the 2001 DIA Annual Meeting, Denver, CO |
Fri Nov 02 13:15:24 EDT 2007 |
| Population Pharmacokinetic (PK) Analysis of Gatifloxacin in Pediatric Patients |
Presented at the 2001 ICAAC Annual Meeting, Chicago, IL |
Fri Nov 02 13:15:24 EDT 2007 |
| An Electronic Strategy for Implementing a New Paradigm in Pediatric Drug Development |
Presented at the 2000 DIA Annual Meeting, Savannah, GA |
Fri Nov 02 13:15:24 EDT 2007 |